¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ °£¼¼Æ÷¾ÏÁ¾(Locally advanced hepatocellular carcinoma) ȯÀÚ¿¡°Ô °£µ¿¸ÆÁÖÀÔ µ¿½Ã Ç×¾ÏÈ­Çйæ»ç¼±¿ä¹ýÀÌ »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ÀÓ»óÈ¿°ú
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

[±Ù°Å±â¹Ý ÀÓ»óÁú¹® ´äº¯]  

 

°£¼¼Æ÷¾ÏÁ¾(Locally advanced hepatocellular carcinoma) ȯÀÚ¿¡°Ô °£µ¿¸ÆÁÖÀÔ µ¿½Ã Ç×¾ÏÈ­Çйæ»ç¼±¿ä¹ýÀÌ »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ÀÓ»óÈ¿°ú

(Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma)

ÀÓ»óÁú¹®

±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¼¼Æ÷¾ÏÁ¾(Locally advanced hepatocellular carcinoma, LAHCC) ȯÀÚ¿¡°Ô °£µ¿¸Æ ÁÖÀÔ µ¿½Ã Ç×¾ÏÈ­Çйæ»ç¼±¿ä¹ý(Hepatic Arterial Infusion Concurrent Chemoradiotherapy, CCRT) Ä¡·á°¡ »ýÁ¸À²(Overall survival, OS)À» ³ôÀ̴µ¥ È¿°úÀûÀԴϱî?

±Ù°Å±â¹Ý ´äº¯

±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¾ÏȯÀÚ Áß CCRTÄ¡·á¸¦ Àû¿ëÇÑ ±×·ìÀº ±×·¸Áö ¾ÊÀº ±×·ìº¸´Ù »ýÁ¸À²ÀÌ ÀǹÌÀÖ°Ô Çâ»óµÇ¾úÀ½À» ³ªÅ¸³»¾ú½À´Ï´Ù.

¼­ÁöÁ¤º¸

Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.  DOI: https://doi.org/10.4143/crt.2014.276

¿¬±¸¸ñÀû

LAHCC ȯÀÚ¿¡°Ô CCRT Ä¡·á°¡  OS¿¡ ¹ÌÄ¡´Â È¿°ú

¿¬±¸¼³°è

A Cohort Study: A Propensity Score Matching Analysis (1992³â~2008³â)

¿¬±¸´ë»ó

LAHCC ȯÀÚ 857¸í

½ÃÇ豺 ÁßÀç

¾Ï¼¾ÅÍ(the Yonsei Cancer Center, YCC)ÀÚ·á: 1992³âºÎÅÍ 2008³â  LAHCC 106¸í

´ëÁ¶±º ÁßÀç

KLCSG ±¹°¡¾ÏÀÚ·á HCC cohort: 2003³âºÎÅÍ 2005³â  LAHCC 751¸í

Æò°¡ÁöÇ¥

»ýÁ¸À²(Overall survival rates between the two groups)

ÁÖ¿ä°á°ú

5³â µ¿¾ÈÀÇ ÄÚȣƮ ÀÚ·á¿Í µÎ°³ÀÇ µ¥ÀÌÅͺ£À̽º ÀÚ·á(Yonsei Cancer Center, YCC and Korean Liver Cancer Study Group, KLCSG)¸¦ ¹ÙÅÁÀ¸·Î ºÐ¼®ÇÑ °á°ú, ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¾ÏȯÀÚ Áß CCRTÄ¡·á¸¦ Àû¿ëÇÑ ±×·ìÀº ±×·¸Áö ¾ÊÀº ±×·ìº¸´Ù »ýÁ¸À²ÀÌ ÀǹÌÀÖ°Ô Çâ»óµÇ¾úÀ½À» ³ªÅ¸³»¾ú½À´Ï´Ù(median OS, 11.4 months; 5-year OS, 10.4%) had significantly better OS than the non-CCRT group (median OS, 6.6 months; 5-year OS, 8.5%; p=0.02).

±Ù°Å¼öÁØ

Moderate

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2015. Medical Research Information Center (MedRIC) Editors

 


2018-09-17 ¿ÀÈÄ 5:33:03, Á¶È¸¼ö : 1445